Literature DB >> 14730048

From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation.

Paula J Woodward1, Keyanoosh Hosseinzadeh, Jeff S Saenger.   

Abstract

Ovarian cancer is the deadliest gynecologic malignancy, with approximately 70% of patients having peritoneal involvement at the time of diagnosis. It spreads predominantly by direct invasion and intraperitoneal dissemination. The staging system is surgically based, with stage I disease being limited to one or both ovaries. In stage II disease, there is extraovarian spread of tumor, but it does not extend beyond the pelvis. Stages III and IV disease are considered advanced, with stage III ovarian cancer including diffuse peritoneal disease involving the upper abdomen and stage IV disease having distant metastases including hepatic lesions. Common sites of intraperitoneal seeding include the omentum, paracolic gutters, liver capsule, and diaphragm. Thickening, nodularity, and enhancement are all signs of peritoneal involvement. Although computed tomography is the most common imaging modality used to stage ovarian cancer, magnetic resonance imaging has been shown to be equally accurate. Currently, however, no imaging modality allows microscopic spread of disease to be ruled out, and a full staging laparotomy is always required. Early ovarian cancer is treated with comprehensive staging laparotomy, whereas advanced but operable disease is treated with primary cytoreductive surgery (debulking) followed by adjuvant chemotherapy. Patients with unresectable disease may benefit from neoadjuvant (preoperative) chemotherapy before debulking.

Entities:  

Mesh:

Year:  2004        PMID: 14730048     DOI: 10.1148/rg.241035178

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  17 in total

Review 1.  ESUR guidelines: ovarian cancer staging and follow-up.

Authors:  Rosemarie Forstner; Evis Sala; Karen Kinkel; John A Spencer
Journal:  Eur Radiol       Date:  2010-09-14       Impact factor: 5.315

Review 2.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

3.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

4.  Role of Imaging in Peritoneal Surface Malignancies.

Authors:  Santosh Krishnamurthy; Raghav Balasubramaniam
Journal:  Indian J Surg Oncol       Date:  2016-06-08

Review 5.  A new dimension of FDG-PET interpretation: assessment of tumor biology.

Authors:  Thomas C Kwee; Sandip Basu; Babak Saboury; Valentina Ambrosini; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 6.  Low-grade epithelial ovarian cancer: what a radiologist should know.

Authors:  Sherif Elsherif; Sanaz Javadi; Chitra Viswanathan; Silvana Faria; Priya Bhosale
Journal:  Br J Radiol       Date:  2019-01-31       Impact factor: 3.039

7.  Patterns of peritoneal spread of tumor in the abdomen and pelvis.

Authors:  Ott Le
Journal:  World J Radiol       Date:  2013-03-28

8.  Multimodality imaging of ovarian cystic lesions: Review with an imaging based algorithmic approach.

Authors:  Ashish P Wasnik; Christine O Menias; Joel F Platt; Usha R Lalchandani; Deepak G Bedi; Khaled M Elsayes
Journal:  World J Radiol       Date:  2013-03-28

9.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

Review 10.  Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI.

Authors:  Rosemarie Forstner
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.